AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23839182
Drug: Doxycycline calcium
RxNorm normalized name: Doxycycline Calcium
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline calcium 1.2 mg/kg/day
Trial: 23839182
Drug: Doxycycline calcium
RxNorm normalized name: Doxycycline Calcium
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline calcium 2.4 mg/kg/day
Trial: 21216540
Drug: Porcilis PCV(®)
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcilis PCV(®) vaccine, 2 mL intramuscular dose
Trial: 21216540
Drug: Diluvac Forte(®)
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluvac Forte(®) adjuvant, 2 mL intramuscular dose
Trial: 17548839
Drug: XELOX (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (oral capecitabine 1,000 mg/m2 bid for 14 days plus oxaliplatin 130 mg/m2 on day 1 every 3 weeks)
Trial: 17548839
Drug: FUOX (continuous‐infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUOX (continuous‐infusion FU 2,250 mg/m2 during 48 hours on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m2 on days 1, 15, and 29 every 6 weeks)
Trial: 11322176
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice daily for 4 days
Trial: 7943103
Drug: Prophylactic amnioinfusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic amnioinfusion (600 ml saline solution bolus followed by 3 ml/min)
Trial: 3307517
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.01 mg/kg atropine sulphate
Trial: 21704238
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 300 mg (test formulation)
Trial: 21704238
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 300 mg (reference formulation)
Trial: 19319953
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg dose of inactivated influenza vaccine
Trial: 19319953
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg dose of inactivated influenza vaccine
Trial: 19319953
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg dose followed by 15 microg booster
Trial: 19319953
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg dose followed by placebo
Trial: 19319953
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg dose followed by placebo
Trial: 9021380
Drug: 3-monthly depot
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly depot leuprolide
Trial: 9021380
Drug: Monthly depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly depot leuprolide
Trial: 1425865
Drug: lansoprazole 10
RxNorm normalized name: lansoprazole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 10 mg
Trial: 1425865
Drug: lansoprazole 20
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lansoprazole 20 mg
Trial: 1425865
Drug: lansoprazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (all doses) after 7 days
Trial: 6438679
Drug: High-nicotine cigarette
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-nicotine cigarette (1.38 mg) (Experiment III)
Trial: 6438679
Drug: Low-nicotine cigarette
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-nicotine cigarette (0.40 mg) (Experiment III)
Trial: 27213441
Drug: DER-diet (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DER-diet (synthetic diet containing daily energy requirements)
Trial: 17474991
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 11 vitamins and 5 minerals for 12 months
Trial: 17474991
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken daily for 12 months
Trial: 15052846
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment consisting of postisometric relaxation, massage of the prostate, and transrectal mobilization of the pelvic ligaments
Trial: 11344184
Drug: rhGH (Saizen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (Saizen, Serono, Switzerland) 0.09 IU/kg body weight (BW) 3 times weekly with dietary intervention
Trial: 2736877
Drug: Lipid-supplemented group
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-supplemented group (one-quarter of glucose energy replaced by intravenous fat)
Trial: 31550819
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgery for rectal GISTs
Trial: 31550819
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment of GIST
Trial: 25919773
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (CT) - rabeprazole-amoxicillin-clarithromycin-metronidazole for 14 days; n=122
Trial: 25919773
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (QT) - rabeprazole-tetracycline-metronidazole-colloidal bismuth subcitrate for 10 days; n=97
Trial: 25919773
Drug: Levofloxacin-based therapy
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based therapy (LT) - rabeprazole-amoxicillin-levofloxacin for 10 days; n=87
Trial: 23731454
Drug: 1072 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1072 nm infrared light therapy
Trial: 23731454
Drug: Placebo (sham)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham) light therapy
Trial: 19372480
Drug: Clear liquid
RxNorm normalized name: Ensure Clear Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear liquid gastric emptying study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid), 30-min duration
Trial: 10883416
Drug: AMP 579
RxNorm normalized name: psyllium 579 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP 579 (50 micrograms/kg as a 6-hour constant-rate intravenous infusion)
Trial: 3782621
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methylphenidate and cognitive therapy
Trial: 3782621
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication during post‐testing)
Trial: 24947950
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg I/V metronidazole and 1 g Ceftriaxone I/V before induction of anesthesia
Trial: 19087155
Drug: Subcutaneous histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous histamine (1-10 ng twice a week)
Trial: 19087155
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (50 U, one injection cycle)
Trial: 12548308
Drug: PABA15 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PABA15 (80 mg at 08:00, 12:00, and 15:00)
Trial: 12548308
Drug: PABA18 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PABA18 (80 mg at 08:00, 12:00, and 18:00)
Trial: 12548308
Drug: Single dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosage of 80 mg PABA
Trial: 12548308
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg PABA at recommended hours
Trial: 12548308
Drug: Recommended dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dosage schedule (PABA taken with main meals)
Trial: 10700656
Drug: Amitriptyline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline treatment for 6 weeks
Trial: 9568324
Drug: Trypsin: chymotrypsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trypsin: chymotrypsin preparation
Trial: 3017804
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (1 g daily enema)
Trial: 3017804
Drug: Prednisolone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (25 mg daily enema)
Trial: 24687506
Drug: Liposomal amikacin
RxNorm normalized name: amikacin liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amikacin for inhalation (LAI) 560 mg
Trial: 21144224
Drug: Steroid-infused carboxymethylcellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-infused carboxymethylcellulose (CMC) foam, 4 mL hydrated with triamcinolone, 40 mg/mL (Kenalog 40)
Trial: 16430197
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at baseline (Group 1)
Trial: 16430197
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at week 24 (Group 2)
Trial: 6336918
Drug: Intravenous cefoxitin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefoxitin in conjunction with standard bowel preparation
Trial: 6336918
Drug: Standard bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bowel preparation
Trial: 19733660
Drug: gelatin capsules
RxNorm normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsules loaded with fast‐disintegrating starch pellets (group P)
Trial: 19733660
Drug: lyophilized lactose/skimmed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilized lactose/skimmed milk (group L)
Trial: 19733660
Drug: all groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all groups (P, L, C)
Trial: 12601075
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (target INR, 1.5 to 2.0)
Trial: 10959813
Drug: Interferon combined
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon combined with ribavirin (1000-1200 mg/day) for 24 weeks
Trial: 1654194
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) treatment with 370 mg of monoclonal antibody 494/32 (100 mg loading dose, 9 x 30 mg continuing within 10 days)
Trial: 1654194
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional anti-cancer treatment (Control)
Trial: 6352612
Drug: Ceftazidime and
RxNorm normalized name: Ceftazidime and Avibactam for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime and tobramycin combination
Trial: 26089136
Drug: Controlled-Release Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-Release Sarpogrelate 300 mg once daily
Trial: 26089136
Drug: Immediate-Release Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-Release Sarpogrelate 100 mg three times daily
Trial: 26089136
Drug: Controlled-Release Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-Release Sarpogrelate
Trial: 26089136
Drug: Immediate-Release Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-Release Sarpogrelate
Trial: 21629370
Drug: Daily functioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily functioning
Trial: 21629370
Drug: Hypnotic consumption
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic consumption
Trial: 19083075
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg of vitamin D3 daily
Trial: 19083075
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg of vitamin D3 daily
Trial: 19083075
Drug: 75 microg
RxNorm normalized name: Norgestrel 75 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microg of vitamin D3 daily
Trial: 19083075
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg of vitamin D3 daily
Trial: 19083075
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of vitamin D3 daily
Trial: 19083075
Drug: S-calcium (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-calcium (not specified dosage)
Trial: 16784967
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg before each meal (300 mg/d) for 3 months
Trial: 16344404
Drug: ISDN/HYD therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN/HYD therapy
Trial: 10596659
Drug: 2,200 mg
RxNorm normalized name: omega 3/dha/epa/other om3/D3 2,200 mg (1,570 mg-610 mg-20 mg)-1,000 unit/5 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,200 mg amoxicillin‐clavulanic acid
Trial: 10596659
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg cefuroxime
Trial: 8691923
Drug: r-hGH treatment
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH treatment (subcutaneous dose ranged between 12.2 and 21.0 U/m2 per week for the first 2 years, then 20 U/m2 per week thereafter)
Trial: 8691923
Drug: Observation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation group (7 short children who declined treatment)
Trial: 29044718
Drug: Child‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child‐ and Family‐Focused Cognitive Behavioral Therapy (CFF‐CBT)
Trial: 29044718
Drug: Psychotherapy treatment‐as‐usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy treatment‐as‐usual (TAU)
Trial: 26883141
Drug: TC-based CCRT
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC-based CCRT (carboplatin AUC: 2, paclitaxel 35mg/m²) followed by TC-based consolidation chemotherapy (carboplatin AUC: 5, paclitaxel 175mg/m²)
Trial: 25402544
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) twice daily (bid)
Trial: 18507956
Drug: Traditional medications
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medications
Trial: 11840081
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose Hib polysaccharide-tetanus toxoid conjugate vaccine
Trial: 11840081
Drug: 1/10 dilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 dilution of Hib polysaccharide-tetanus toxoid conjugate vaccine
Trial: 10354656
Drug: Lithium (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (1,200 mg)
Trial: 8577796
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (70 mg)
Trial: 8577796
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (250 mg)
Trial: 1959958
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days
Trial: 1959958
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days (if started by 16-19 weeks of gestation)
Trial: 31675919
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (600,000 IU of 25(OH)D in a single oral administration)
Trial: 29246284
Drug: ALA-DAG (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-DAG (2.5 g/day)
Trial: 29246284
Drug: ALA-TAG (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-TAG (2.5 g/day)
Trial: 26672246
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine comprehensive treatment only)
Trial: 21471262
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion starting after induction of anesthesia with an initial bolus of 12 μg·kg(‐1) for 10 min, followed by 0.1 μg·kg(‐1)·min(‐1) for 24 h
Trial: 15121557
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600 microg misoprostol
Trial: 15121557
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of 600 microg misoprostol
Trial: 11477729
Drug: Aerosolized INS
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized INS 365 (20, 40, 80, and 100 mg)
Trial: 11477729
Drug: Aerosolized INS
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized INS 365 (80 mg and 100 mg)
Trial: 25312436
Drug: Perindopril-indapamide (4/1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril-indapamide (4/1.25 mg)
Trial: 14516415
Drug: Ketorolac (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (10 mg, p.o.)
Trial: 8859174
Drug: Regional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional infusion chemotherapy with FUDR
Trial: 2983461
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir 200 mg X 4 daily for 28 days
Trial: 2983461
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir (after interruption of placebo)
Trial: 2983461
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir and placebo
Trial: 31664468
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 100-150 mg/kg/min
Trial: 29521134
Drug: Tylerdipine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tylerdipine hydrochloride (5, 15, 20, 25, and 30 mg)
Trial: 26574928
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with fixed appliance for 6 months
Trial: 26574928
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group awaiting treatment
Trial: 25183688
Drug: Probiotic L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic L. plantarum IS-10506 (10(10)CFU/day)
Trial: 25183688
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of probiotic L. plantarum IS-10506 (10(10)CFU/day) and zinc (8mg elemental zinc)
Trial: 20482515
Drug: Oral naltrexone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone, 50 mg
Trial: 20482515
Drug: Intramuscular naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naltrexone (active for one month)
Trial: 20482515
Drug: Oral naltrexone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone, higher doses
Trial: 15228129
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5%/clindamycin 1% topical gel (BP/C)